Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

CYP Induction (mRNA) / HepaRG

Cytochrome P450 (CYP) induction by a drug can accelerate the metabolism of a co-administered victim drug significantly, causing serious drug-drug interactions.

To date induction of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 have been described. Whilst CYP1A2 induction involves the Aryl hydrocarbon receptor (AhR) and induction of CYP2B6 is mediated by the constitutive androstane receptor (CAR), the CYP2C isoforms and CYP3A4 are co-induced via the pregnane X receptor (PXR). Therefore, the current FDA guidelines suggest to investigate induction of CYP1A2, CYP2B6 and CYP3A4.

Traditionally, CYP induction has been measured via the assessment of enzyme activity in human hepatocytes. To address inter-individual variability, hepatocyte preparations from at least three donors had to be used.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.